Xiaojun Liu

Xiaojun Liu is a seasoned professional with extensive experience in AAV/LV process development, CMC, pDNA, and mRNA production. Currently serving as the Director and Head of AAV/LV Process Development at ReciBioPharm since March 2023, Xiaojun Liu directs operations to optimize viral vector productivity and quality while developing customized AAV platforms. Previous roles include Associate Director at EdiGene Biotechnology USA, where leadership in AAV research and development was demonstrated, and Associate Editor for Molecular Biotechnology at Springer Publishing, providing peer review and editorial management for numerous manuscripts. Xiaojun Liu's academic foundation includes a Ph.D. in Genetics from Fudan University, complemented by MS and BS degrees in Genetics and Biotechnology from Sichuan University. With a robust publication record and a history of successful collaborations in gene therapy, Xiaojun Liu is recognized for significant contributions in advancing biotechnology and gene delivery systems.